WA
ALNY icon

Waverly Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Waverly Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Buy
907
+67
+8% +$22.8K ﹤0.01% 1299
2025
Q4 		$334K Sell
840
-25
-3% -$11.1K ﹤0.01% 1165
2025
Q3 		$394K Buy
+865
New +$352K ﹤0.01% 940

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Waverly Advisors's ALNY Position: Q1 2026 in Review

Waverly Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 8% in Q1 2026, buying an estimated $22.8K and bringing the position to 907 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Waverly Advisors first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $394K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Waverly Advisors held 907 shares of Alnylam Pharmaceuticals worth $300K as of Q1 2026.
  • Waverly Advisors bought 67 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $22.8K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Waverly Advisors's portfolio in Q1 2026, its #1299 holding.
  • Waverly Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Waverly Advisors's Alnylam Pharmaceuticals position peaked at $394K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.